14729-D9831C00002- 1 Month Biopsy Study (Biopsy)
A Double-blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Frieburg, Deutschland
- Research Site
-
GROßHANSDORF, Deutschland
- Research Site
-
Hannover, Deutschland
- Research Site
-
-
-
-
-
Amsterdam, Niederlande
- Research Site
-
-
-
-
-
Leicester, Vereinigtes Königreich
- Research Site
-
London, Vereinigtes Königreich
- Research Site
-
Manchester, Vereinigtes Königreich
- Research Site
-
Newcastle upon Tyne, Vereinigtes Königreich
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men or women 40 years or above
- FEV1 between 40 and 80% of predicted normal value post-bronchodilator
- Clinical diagnosis of COPD
Exclusion Criteria:
- Other clinically relevant disease or disorders
- Exacerbation of COPD within 30 days
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
|
Placebo
|
|
Experimental: AZD1981
|
Oral tablet, twice daily, 4 weeks treatment
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Aggregated Pathology Score
Zeitfenster: Before and after 1 month treatment
|
Composite endpoint subscores: histological grade, immunohistochemistry grade, leucocyte counts.
Each subscore measured on scale 1 (normal) to 5 (worst outcome).
Composite score summed across the subscores, ranging from 3 (normal) to 15 (worst outcome).
Change from baseline.
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Eosinophil Count (%)
Zeitfenster: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Eosinophil count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Neutrophil Count (%)
Zeitfenster: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Neutrophil count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Macrophages Count (%)
Zeitfenster: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Macrophages count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Lymphocytes Count (%)
Zeitfenster: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Lymphocytes count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Epithelial Cells Count (%)
Zeitfenster: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Epithelial cells count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Total Cells Count
Zeitfenster: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Total cells count from baseline
|
Before and after 1 month treatment
|
|
Induced Sputum: Eosinophil Count (%)
Zeitfenster: Before and after 3 week treatment
|
Change in Induced sputum Eosinophil count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Neutrophils Count (%)
Zeitfenster: Before and after 3 week treatment
|
Change in Induced sputum Neutrophils count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Macrophages Count (%)
Zeitfenster: Before and after 3 week treatment
|
Change in Induced sputum Macrophages count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Lymphocytes Count (%)
Zeitfenster: Before and after 3 week treatment
|
Change in Induced sputum Lymphocytes count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Epithelial Cells Count (%)
Zeitfenster: Before and after 3 week treatment
|
Change in Induced sputum Epithelial cells count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Total Cells Count
Zeitfenster: Before and after 3 week treatment
|
Change in Induced sputum Total cells count from baseline
|
Before and after 3 week treatment
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Forced Expiratory Volume in 1 Second (FEV1)
Zeitfenster: Before and after 1 month treatment
|
Change in Forced Expiratory Volume in 1 second (FEV1) from baseline to end of treatment
|
Before and after 1 month treatment
|
|
Clinical Chronic Obstructive Pulmonary Disease (COPD) The Clinical COPD Questionnaire (CCQ)
Zeitfenster: Before and after 1 month treatment
|
Change in total CCQ score from baseline to last measurement on treatment.
scored on a scale of 0 - 6. 0 =(low symptoms)-6 =(high symptoms)
|
Before and after 1 month treatment
|
|
Peak Expiratory Flow (PEF) Morning
Zeitfenster: Before and after 1 month treatment
|
Mean change in Peak Expiratory Flow (PEF) morning from baseline to the average of the treatment period
|
Before and after 1 month treatment
|
|
Peak Expiratory Flow (PEF) Evening
Zeitfenster: Before and after 1 month treatment
|
Mean change in Peak Expiratory Flow (PEF) evening from baseline to the average of the treatment period
|
Before and after 1 month treatment
|
|
Chronic Obstructive Pulmonary Disease (COPD) Symptom Night-time Awakenings Score
Zeitfenster: Before and after 1 month treatment
|
Mean change in COPD symptom night-time awakening score from baseline to the average of the treatment period.
0=(no symptom)-4=(no sleep)
|
Before and after 1 month treatment
|
|
Chronic Obstructive Pulmonary Disease (COPD) Symptom Breathing Score
Zeitfenster: Before and after 1 month treatment
|
Mean change in COPD symptom breathing score from baseline to the average of the treatment period.
0= (none) - 4 =(severe).
|
Before and after 1 month treatment
|
|
Chronic Obstructive Pulmonary Disease (COPD) Symptom Cough Score
Zeitfenster: Before and after 1 month treatment
|
Mean change in COPD symptom cough score from baseline to the average of the treatment period.
0= (none) - 4= (almost constant)
|
Before and after 1 month treatment
|
|
Chronic Obstructive Pulmonary Disease (COPD) Symptom Sputum Score
Zeitfenster: Before and after 1 month treatment
|
Mean change in COPD symptom sputum score from baseline to the average of the treatment period.
0= (none) - 4= (severe).
|
Before and after 1 month treatment
|
|
Adverse Event (AE)
Zeitfenster: 1 month
|
Number of participants with an Adverse Event
|
1 month
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Norbert Krug, Fraunhofer Institute
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- D9831C00002
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .